Citation

Meha S, Suhas S, Rao NP. Psychiatry Res. Case Rep. 2023; 2(1): e100100.

Copyright

(Copyright © 2023, Elsevier Publishing)

DOI

10.1016/j.psycr.2022.100100

PMID

36597498

PMCID

PMC9800325

Abstract

Every second patient who suffers from COVID-19 experiences is at risk for depression. The treatment of severe depression with suicidal risk is challenging in patients with COVID-19 given the restrictions in access to and safety concerns with the use of electroconvulsive therapy during the COVID pandemic. Although ketamine is effective in treating depression, especially in presence of acute suicidality, to date, there are no reports on ketamine use to treat severe depression in the context of COVID-19. In this case report, we describe the success of ketamine to treat a person with severe depression and suicidality following COVID-19 infection.

Language: en

Keywords

Case report; COVID-19; Depression; Electroconvulsive therapy; Ketamine; Pharmacotherapy; Suicide; Treatment